Clinical Trial Update: The Effect of Xenical on Weight and Risk Factors [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Xenical (orlistat) on weight change and cardiovascular risk factors in obesity and cardiovascular disease. The study status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Obesity

Drugs mentioned

• XENICAL (orlistat)

Snippet

Sponsor: University of British Columbia | Conditions: Obesity, Heart Diseases | Phase 4 | Status: COMPLETED